Capillary malformation
MONDO:0016231Also known as: congenital malformation of capillary, rare capillary malformation
46 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aims to tame rare bleeding disorder
Disease control OngoingThis study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. First, healthy volunteers will receive a single dose to check safety. Then, HHT patients will recei…
Phase: PHASE1, PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug shows promise for rare bleeding disorder
Disease control OngoingThis phase 2 trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron-deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal blood vessels that bleed easily. The study involves 33 adul…
Phase: PHASE2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
HHT drug trial pulled before it even started
Disease control TerminatedThis was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn bef…
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a cancer pill stop debilitating nosebleeds? new trial hopes so.
Disease control OngoingThis study tests whether a low dose of pazopanib, a drug currently used for cancer, can reduce severe nosebleeds and improve anemia in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will take either the drug or a placebo daily for 24 weeks. Researc…
Phase: PHASE2, PHASE3 • Sponsor: Cure HHT • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to stop nosebleeds in rare genetic disorder
Disease control OngoingThis study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces the number, length, and sever…
Phase: PHASE1, PHASE2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a cancer drug tame rare bleeding Disorder's heart complications?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug bevacizumab can help people with a rare condition called hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems leading to high heart output and possible heart failure. Researchers will check heart function before and after…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New imaging technique could sharpen laser treatment for birthmarks
Knowledge-focused OngoingThis study uses a special imaging device called optical coherence tomography (OCT) to look at blood vessels in vascular stains (a type of birthmark). Researchers want to see if the size and depth of these vessels relate to the birthmark's genetics. About 73 people with vascular s…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused OngoingThis study is creating a registry of people with Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessels and frequent nosebleeds. Researchers will collect health information from about 1,000 adults over many years to see how the disease ch…
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC